Gilead Sciences, Inc.
NEWS
Gilead Sciences announced it exercised its options to three of Arcus Biosciences’ programs. Two are anti-TIGIT molecules, domvanalimab and AB308, and the other is etrumadenant and quemliclustat.
Vaccinations will be required by January 4 under the new White House plan.
Shoreline Biosciences secured $140 million in financing to accelerate the growth of its induced pluripotent stem cells (iPSC)-based immunotherapies and support the expansion of its manufacturing capabilities.
BlueSphere Bio aims to overcome challenges in the CAR T space with a precision approach to T cell therapy.
Gilead Sciences has one of the most robust HIV pipelines in the world. New real-world data from the ongoing BICSTaR study demonstrates benefits of HIV drug Biktarvy.
Yet another busy week for clinical trial news. Here’s a look.
The upcoming changes will be less disruptive but will have far-reaching consequences throughout the pharmaceutical supply chain.
AT-527, an oral direct-acting antiviral agent that blocks viral RNA polymerase needed for viral replication, failed to meet its primary endpoint in the Phase II MOONSONG study.
CRISPR Therapeutics provided updated data from its ongoing Phase I CARBON trial of CTX110, its allogeneic “off-the-shelf” CAR-T therapy for CD19+ B-cell cancers.
JOBS
IN THE PRESS